[Skip to Navigation]
Sign In
Views 302
Citations 0
Comment & Response
January 30, 2020

Variant Interpretation in Patients With Metastatic Breast Cancer—Reply

Author Affiliations
  • 1Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
JAMA Oncol. 2020;6(4):582-583. doi:10.1001/jamaoncol.2019.6409

In Reply We thank Fostira and Konstantopoulou for their comments regarding our study.1 Indeed, the initial focus of our work was to determine whether patients with metastatic breast cancer might benefit from the recent US Food and Drug Administration approval of polyadenosine diphosphate–ribose polymerase inhibitors if tested in a relatively unbiased way. We acknowledge that patients with pathogenic BRCA1/2 variants all met National Comprehensive Cancer Network guidelines, as mentioned in our article.1 However, equally important, 2 of 6 patients were never tested despite meeting guidelines, which underscores the need for increased dissemination and implementation of germline testing for optimal patient care.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words